Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focusing on extrachromosomal DNA (ecDNA) biology, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's executives, Zachary Hornby (President and CEO) and Jami Rubin (CFO), will engage in a fireside chat session on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.
Boundless Bio aims to develop transformative therapies for patients with previously intractable oncogene amplified cancers. Interested parties can access a live and archived webcast of the session through the 'Events & Presentations' section of the company's website under the Investors tab.
Boundless Bio (Nasdaq: BOLD), una compagnia oncologica in fase clinica che si concentra sulla biologia del DNA extrachromosomico (ecDNA), ha annunciato la sua partecipazione alla 2024 Cantor Global Healthcare Conference. I dirigenti dell'azienda, Zachary Hornby (Presidente e CEO) e Jami Rubin (CFO), parteciperanno a una sessione di colloqui informali il mercoledì 18 settembre 2024, alle 10:20 a.m. ET a New York, NY.
Boundless Bio mira a sviluppare terapie transformative per pazienti affetti da cancro con amplificazioni oncogene precedentemente intrattabili. Le parti interessate possono accedere a una webcast in diretta e registrata della sessione attraverso la sezione 'Eventi e Presentazioni' del sito web dell'azienda sotto la scheda Investitori.
Boundless Bio (Nasdaq: BOLD), una empresa de oncología en etapa clínica que se centra en la biología del ADN extraconómico (ecDNA), ha anunciado su participación en la 2024 Cantor Global Healthcare Conference. Los ejecutivos de la empresa, Zachary Hornby (Presidente y CEO) y Jami Rubin (CFO), participarán en una sesión de charla informal el miércoles 18 de septiembre de 2024, a las 10:20 a.m. ET en Nueva York, NY.
Boundless Bio tiene como objetivo desarrollar terapias transformadoras para pacientes con cánceres amplificados por oncógenos previamente intratables. Las partes interesadas pueden acceder a una transmisión web en vivo y grabada de la sesión a través de la sección 'Eventos y Presentaciones' en el sitio web de la empresa bajo la pestaña de Inversionistas.
Boundless Bio (Nasdaq: BOLD), 엑스트라크로모좀 DNA(ecDNA) 생물학에 중점을 둔 임상 단계의 종양학 회사가 2024 캔터 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 임원인 자커리 혼비 (사장 겸 CEO)와 자미 루빈 (CFO)은 2024년 9월 18일 수요일 오전 10시 20분 ET에 뉴욕(NY)에서 편안한 대화 세션에 참여할 예정입니다.
Boundless Bio는 이전의 치료가 어려운 암 유전자 증폭 암 환자를 위한 변혁적인 치료법을 개발하는 것을 목표로 하고 있습니다. 관심 있는 분들은 회사 웹사이트의 '이벤트 및 발표' 섹션에서 투자자 탭 아래에 있는 세션의 실시간 및 아카이브된 웹캐스트에 접속할 수 있습니다.
Boundless Bio (Nasdaq: BOLD), une entreprise oncologique en phase clinique axée sur la biologie de l'ADN extrachromosomique (ecDNA), a annoncé sa participation à la 2024 Cantor Global Healthcare Conference. Les dirigeants de l'entreprise, Zachary Hornby (Président et CEO) et Jami Rubin (CFO), participeront à une session de discussion informelle le mercredi 18 septembre 2024, à 10h20 ET à New York, NY.
Boundless Bio vise à développer des thérapies transformantes pour les patients atteints de cancers amplifiés par oncogènes précédemment intraitables. Les personnes intéressées peuvent accéder à un webinaire en direct et archivé de la session via la section 'Événements & Présentations' du site web de l'entreprise sous l'onglet Investisseurs.
Boundless Bio (Nasdaq: BOLD), ein klinisches Unternehmen im Bereich der Onkologie, das sich auf die Biologie der extrachromosomalen DNA (ecDNA) konzentriert, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. Die Unternehmensleiter, Zachary Hornby (Präsident und CEO) sowie Jami Rubin (CFO), werden am Mittwoch, den 18. September 2024, um 10:20 Uhr ET in New York, NY an einer lockeren Gesprächsrunde teilnehmen.
Boundless Bio hat das Ziel, transformative Therapien für Patienten mit zuvor behandlungsresistenten, amplifizierten Onkogen-Krebsarten zu entwickeln. Interessierte können über den Bereich 'Veranstaltungen & Präsentationen' auf der Unternehmenswebsite unter dem Tab 'Investoren' auf eine lebendige und archivierte Websuche der Sitzung zugreifen.
- None.
- None.
SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in the 2024 Cantor Global Healthcare Conference.
A fireside chat session is scheduled for Wednesday, September 18, 2024, in New York, NY, at 10:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than
For more information, visit www.boundlessbio.com.
Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com
Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com
FAQ
When is Boundless Bio (BOLD) participating in the 2024 Cantor Global Healthcare Conference?
Who will represent Boundless Bio (BOLD) at the 2024 Cantor Global Healthcare Conference?
How can investors access Boundless Bio's (BOLD) presentation at the 2024 Cantor Global Healthcare Conference?
What is the main focus of Boundless Bio's (BOLD) research and development?
